Defective plasmacytoid dendritic cell-NK cell cross-talk in HIV infection

AIDS Research and Human Retroviruses

Volumn 25, Issue 10, 2009, Pages 1029-1037

  Reitano, K N ^a   Kottilil, S ^a   Gille, C M ^a   Zhang, X ^a   Yan, M ^a   O'Shea, M A ^b   Roby, G ^b   Hallahan, C W ^a   Yang, J ^a   Lempicki, R A ^a   Arthos, J ^a   Fauci, A S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Critical Care Medicine Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GLYCOPROTEIN; GLYCOPROTEIN GP 120; INTEGRIN ALPHA4BETA7; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EX VIVO STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERODIAGNOSIS; VIREMIA;

DENDRITIC CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; INTEGRINS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; PROTEIN BINDING; TUMOR NECROSIS FACTOR-ALPHA; VIREMIA;

EID: 70449482630     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0311     Document Type: Article

References (37)

1. Trinchieri G: Biology of natural killer cells. Adv immunol 1989;47:187-376.
2. Smyth MJ, Godfrey DI, and Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat immunol 2001;2(4):293-299.
3. Long EO: Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999;17:875-904.
4. Lanier LL: On guard--activating NK cell receptors. Nat Immunol 2001;2(1):23-27.
5. Moretta A, Bottino C, Vitale M, et al.: Activating receptors and coreceptors involved in human natural killer cellmediated cytolysis. Annu Rev Immunol 2001;19:197-223.
6. Mavilio D, Benjamin J, Daucher M, et al.: Natural killer cells in HIV-1 infection: Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci USA 2003;100(25):15011- 15016.
7. Cooper MA, Fehniger TA, and Caligiuri MA: The biology of human natural killer-cell subsets. Trends Immunol 2001; 22(11):633-640.
8. Fauci AS, Pantaleo G, Stanley S, and Weissman D: Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996;124(7):654-663.
9. Fauci AS, Mavilio D, and Kottilil S: NK cells in HIV infection: Paradigm for protection or targets for ambush. Nat Rev 2005;5(11):835-843.
10. Kottilil S, Shin K, Jackson JO, et al.: Innate immune dysfunction in HIV infection: Effect of HIV envelope-NK cell interactions. J Immunol 2006;176(2):1107-1114.
11. Martinelli E, Cicala C, Van Ryk D, et al.: HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2007;104(9):3396-3401.
12. Ashkar AA and Rosenthal KL: Toll-like receptor 9, CpGDNA and innate immunity. Curr Mol Med 2002;2(6):545-556.
13. Marshall JD, Heeke DS, Abbate C, Yee P, and Van Nest G: Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha. Immunology 2006;117(1):38-46.
14. Kottilil S, Chun TW, Moir S, et al.: Innate immunity in human immunodeficiency virus infection: Effect of viremia on natural killer cell function. J Infect Dis 2003;187(7):1038-1045.
15. Meyers JH, Justement JS, Hallahan CW, et al.: Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS ONE 2007;2(5):e458.
16. Lempicki RA, Polis MA, Yang J, et al.: Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: Class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 2006;193(8):1172-1177.
17. Arthos J, Cicala C, Martinelli E, et al.: HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008;9(3):301-309.
18. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev 2006;5(6):471-484.
19. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, and Heeg K: CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. Eur J Immunol 1997;27(9):2340-2344.
20. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, and Krieg AM: Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997;94(20): 10833-10837.
21. Aderem A and Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000; 406(6797):82-787.
22. Bauer M, Heeg K, Wagner H, and Lipford GB: DNA activates human immune cells through a CpG sequencedependent manner. Immunology 1999;97(4):699-705. (Pubitemid 29356422)
23. Hartmann G, Weiner GJ, and Krieg AM: CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999;96(16):9305-9310.
24. Sivori S, Carlomagno S, Moretta L, and Moretta A: Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells. Eur J Immunol 2006;36(4):961-967.
25. Harandi AM, Eriksson K, and Holmgren J: A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 2003;77(2):953-962.
26. Gerosa F, Gobbi A, Zorzi P, et al.: The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005;174(2):727-734.
27. Martinson JA, Roman-Gonzalez A, Tenorio AR, et al.: Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. Cell Immunol 2007; 250(1-2):75-84.
28. Tilton JC, Manion MM, Luskin MR, et al.: Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. J Virol 2008;82(8):3997-4006.
29. Alter G, Suscovich TJ, Teigen N, et al.: Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol 2007;178(12):7658- 7666.
30. Tomescu C, Chehimi J, Maino VC, and Montaner LJ: NK cell lysis of HIV-1-infected autologous CD4 primary T cells: Requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. J Immunol 2007;179(4):2097-2104.
31. Azzoni L, Rutstein RM, Chehimi J, Farabaugh MA, Nowmos A, and Montaner LJ: Dendritic and natural killer cell subsets associated with stable or declining CD4+ cell counts in treated HIV-1-infected children. J Infect Dis 2005;191(9): 1451-1459.
32. Finke JS, Shodell M, Shah K, Siegal FP, and Steinman RM: Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J Clin Immunol 2004;24(6):647-652.
33. Killian MS, Fujimura SH, Hecht FM, and Levy JA: Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment. AIDS 2006;20(9):1247-1252.
34. Schmidt B, Fujimura SH, Martin JN, and Levy JA: Variations in plasmacytoid dendritic cell (PDC) and myeloid dendritic cell (MDC) levels in HIV-infected subjects on and off antiretroviral therapy. J Clin Immunol 2006;26(1): 55-64.
35. Cohen OJ, Pantaleo G, Schwartzentruber DJ, Graziosi C, Vaccarezza M, and Fauci AS: Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10 (Suppl. 1):S6-14.
36. Simon V and Ho DD: HIV-1 dynamics in vivo: Implications for therapy. Nat Rev 2003;1(3):181-190.
37. Letvin NL and Walker BD: Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 2003; 9(7):861-866.